Hospitalist Doctors in Manchester, CT Accepting Medicare

10 Hospitalist doctors found. Showing 1 - 10

Robert C Morgan, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 71 Haynes St, Suite 1221, Manchester, CT 06040 Phone: 860-533-6595

Salah Alsalahi, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 71 Haynes St, Manchester, CT 06040 Phone: 860-646-1222

Syera Mathews, M.D Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 71 Haynes St, Manchester Memorial Hospital, Manchester, CT 06040 Phone: 860-646-1222    Fax: 860-533-2975

Edward Sampt, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 71 Haynes St, Suite 1221, Manchester, CT 06040 Phone: 860-533-6595

Faria Mahmood, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 71 Haynes St, Suite 1221, Manchester, CT 06040 Phone: 860-533-6595

Uma Rani Madhusudana, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 71 Haynes St, Manchester, CT 06040 Phone: 860-646-1222

Nermina Bukalo, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 71 Haynes St, Manchester, CT 06040 Phone: 860-540-6595

Cesar Fabian Fuentes, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 71 Haynes St, Manchester, CT 06040 Phone: 860-533-6595    Fax: 860-533-6594

Dr. Savita Nirav Sheth, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 71 Haynes St, Suite 1209, Manchester, CT 06040 Phone: 860-533-6595    Fax: 860-533-6594

Dr. Paula Lucine Chakerian, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 71 Haynes St, Manchester, CT 06040 Phone: 203-739-6959    Fax: 203-739-6959

News Archive

ISTA Pharmaceuticals files sNDA for bromfenac ophthalmic solution

ISTA Pharmaceuticals, Inc., today announced the Company submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for bromfenac ophthalmic solution dosed once-daily as a treatment for ocular inflammation and pain following cataract surgery.

Cell study may yield new treatment strategies for debilitating diseases

A Los Alamos National Laboratory toxicologist and a multidisciplinary team of researchers have documented potential cellular damage from "fullerenes"-soccer-ball-shaped, cage-like molecules composed of 60 carbon atoms. The team also noted that this particular type of damage might hold hope for treatment of Parkinson's disease, Alzheimer's disease, or even cancer.

AVEO Pharmaceuticals completes initial public offering of 9M common stock shares at $9.00 per share

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the completion of its initial public offering of 9,000,000 shares of its common stock. All shares were sold at an initial public offering price of $9.00 per share, resulting in aggregate net proceeds to AVEO of approximately $72,580,000 after deducting underwriting discounts and commissions and estimated offering expenses.

New migraine-associated mechanism discovered

A mutation in the gen that codes the ionic channel TRESK -involved in the control of neuron irritability- causes the dysfunction of some neurons that increase neuronal activity and induce migraine pain.

States mull methods to raise health exchange awareness, provide consumer assistance

California has more uninsured people than other states have people. With that in mind, think about this: By Oct. 1, the state has to have its health insurance exchange up and running, ready to offer an estimated five million people some kind of insurance.

Read more Medical News

› Verified 6 days ago